Ridaforolimus

N/A

Report date: 2026/03/06 13:38:02
NME

Base Information

Drug NameRidaforolimus
Drug Alias NameRidaforolimusum利罗莫司BioNIR地磷莫司EluNIR +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMammalian target of Rapamycin (mTORC1) inhibitorsmTOR Complex 2 inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisMyelodysplastic Syndromes +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesAriad
China Registration ClassN/A

Develop Information

Active CompaniesAriad Pharmaceuticals Inc
Inactive CompaniesUT Health San AntonioNational Cancer InstituteMerck Sharp & Dohme LLC
Active IndicationsCoronary Restenosis
Inactive IndicationsSolid tumoursPrimary MyelofibrosisMyelodysplastic Syndromes +[22] 

Other Information

ATC CodeL01EG03
Related LinksWikipediaKEGG